Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | NAMPT | P43490 | 2/20 | 0.72 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.62 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.62 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31054249 | 1.00 | NPC1 (1.00) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL5655823 | 0.94 | NPC1 (0.88) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL5658310 | 0.94 | NPC1 (0.88) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL29639124 | 0.90 | NPC1 (0.81) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL5661569 | 0.90 | NPC1 (0.81) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL28741230 | 0.90 | NPC1 (0.81) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL5657576 | 0.89 | NPC1 (0.78) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL5658555 | 0.89 | NPC1 (0.78) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL30741445 | 0.88 | NPC1 (0.79) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL4890353 | 0.88 | NPC1 (0.79) | NPC1POLBMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731204-A2 | SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4731619-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF BISPECIFIC RBP4/TTR LIGAND AND C20-D3-RETINOL | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4731618-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF SELECTIVE TTR LIGAND AND C20-D3-RETINOL | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | claimed |
| US-20250387433-A1 | COMPOSITION FOR PREVENTING OR TREATING RETINAL DEGENERATIVE DISEASE CONTAINING EXOSOMES EXTRACTED FROM MESENCHYMAL STEM CELLS | SEOUL NATIONAL UNIVERSITY HOSPITAL (KR) | 2025-12-25 | — | — | US | claimed |
| US-12473302-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-11-18 | — | — | US | claimed |
| US-20250320218-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-10-16 | — | — | US | claimed |
| WO-2024263751-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF SELECTIVE TTR LIGAND AND C20-D3-RETINOL FOR ELIMINATION OF MECHANISM-BASED OCULAR ADVERSE EFFECTS IN TREATING MACULAR DEGENERATION AND TTR AMYLOIDOSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-26 | — | — | WO | claimed |
| WO-2024263790-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR ELIMINATION OF MECHANISM-BASED OCULAR ADVERSE EFFECTS IN TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-26 | — | — | WO | claimed |
| WO-2024263782-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF BISPECIFIC RBP4/TTR LIGAND AND C20-D3-RETINOL FOR ELIMINATION OF MECHANISM-BASED OCULAR ADVERSE EFFECTS IN TREATING MACULAR DEGENERATION AND TTR AMYLOIDOSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-26 | — | — | WO | claimed |
| US-12168664-B2 | Triazolopyrimidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-17 | — | — | US | claimed |
| US-20030225268-A1 | Diazabicyclic CNS active agents | ABBVIE INC. | 2003-12-04 | — | — | US | claimed |
| US-6656958-B2 | Preferred compounds are 3'-(5'- and/or 6'-substituted) pyridyl ethers; selectively controlling neurotransmitter release in mammals using these compounds | ABBOTT LABORATORIES | 2003-12-02 | — | — | US | claimed |
| EP-1359152-A2 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LABORATORIES (US) | 2003-11-05 | — | — | EP | claimed |
| EP-1147112-B1 | DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ABBOTT LAB (US) | 2003-10-29 | — | — | EP | claimed |
| US-6477416-B1 | System and method for automatically and adaptively segmenting an atrial blanking period | PACESETTER, INC. | 2002-11-05 | — | — | US | claimed |
| JP-2002535409-A | — | — | 2002-10-22 | — | — | JP | claimed |
| US-6327499-B1 | Cardiac stimulator and defibrillator | ADVANCED MEDICAL DEVICES, S.A. (LU) | 2001-12-04 | — | — | US | claimed |
| EP-1147112-A1 | DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000044755-A1 | DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2000-08-03 | — | — | WO | claimed |
| CN-1063686-A | With the synthetic vesnarinone of active ester method | MEDICINE INST HUAXI MEDICAL UN (CN) | 1992-08-19 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168664-B2 | Triazolopyrimidines, their preparation and use | ABL1, CBR3, DPYD | NPC1 3520/4885POLB 2030/4885MAPT 4406/4885 |
| US-12473302-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, DRD3 | NPC1 3005/4885POLB 3536/4885MAPT 3601/4885 |
| US-20250387433-A1 | COMPOSITION FOR PREVENTING OR TREATING RETINAL DEGENERATIVE DISEASE CONTAINING EXOSOMES EXTRACTED FROM MESENCHYMAL STEM CELLS | EXOSC9, EXOSC5, MTREX | NPC1 968/4885POLB 4325/4885MAPT 175/4885 |
| US-20030225268-A1 | Diazabicyclic CNS active agents | GABRE, GRIN1, CNTN1 | NPC1 440/4885POLB 4480/4885MAPT 2125/4885 |
| US-20250320218-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HRH4, HRH3, HRH2 | NPC1 1790/4885POLB 3378/4885MAPT 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.